DACOMITINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 76 adverse event reports in the FDA FAERS database where DACOMITINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for DACOMITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 253 | 37.1% | 253 | 18 |
| Diarrhoea | 114 | 16.7% | 23 | 36 |
| Rash | 108 | 15.8% | 22 | 17 |
| Neoplasm progression | 78 | 11.4% | 39 | 14 |
| Paronychia | 55 | 8.1% | 5 | 10 |
| Blood pressure increased | 47 | 6.9% | 9 | 7 |
| Off label use | 35 | 5.1% | 10 | 10 |
| Pruritus | 34 | 5.0% | 7 | 9 |
| Dyspnoea | 30 | 4.4% | 7 | 13 |
| Carcinoembryonic antigen increased | 28 | 4.1% | 5 | 2 |
| Pain | 28 | 4.1% | 4 | 7 |
| Decreased appetite | 27 | 4.0% | 13 | 8 |
| Malignant neoplasm progression | 26 | 3.8% | 11 | 6 |
| Vomiting | 26 | 3.8% | 10 | 9 |
| Asthenia | 24 | 3.5% | 6 | 8 |
Other Indications for DACOMITINIB
Non-small cell lung cancer (103)
Lung adenocarcinoma (63)
Lung cancer metastatic (39)
Non-small cell lung cancer metastatic (36)
Lung adenocarcinoma stage iv (12)
Product used for unknown indication (10)
Non-small cell lung cancer stage iv (7)
Targeted cancer therapy (7)
Adenocarcinoma (6)
Egfr gene mutation (6)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)